Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease - PubMed (original) (raw)
Selective loss of 20S proteasome alpha-subunits in the substantia nigra pars compacta in Parkinson's disease
Kevin St P McNaught et al. Neurosci Lett. 2002.
Abstract
The proteolytic activities of 26/20S proteasomes are impaired in the substantia nigra pars compacta (SNc) in sporadic Parkinson's disease (PD). In the present study, we examined the structural integrity of the proteasome by determining the levels of the beta- and alpha-subunits which together normally constitute the catalytic core of 26/20S proteasomes. Western blot analyzes and immunohistochemical staining revealed a major and selective loss of alpha-subunits in dopaminergic neurons of the SNc but not in other brain regions in sporadic PD. This defect is known to cause the proteasome to become unstable and prevents its assembly with resultant impairment of enzymatic activity. Thus, structural and function defects in 26/20S proteasomes may underlie protein accumulation, formation of proteinaceous Lewy bodies and dopaminergic neuronal death in the SNc in sporadic PD.
Similar articles
- Altered proteasomal function in sporadic Parkinson's disease.
McNaught KS, Belizaire R, Isacson O, Jenner P, Olanow CW. McNaught KS, et al. Exp Neurol. 2003 Jan;179(1):38-46. doi: 10.1006/exnr.2002.8050. Exp Neurol. 2003. PMID: 12504866 - Proteasome inhibition causes nigral degeneration with inclusion bodies in rats.
McNaught KS, Björklund LM, Belizaire R, Isacson O, Jenner P, Olanow CW. McNaught KS, et al. Neuroreport. 2002 Aug 7;13(11):1437-41. doi: 10.1097/00001756-200208070-00018. Neuroreport. 2002. PMID: 12167769 - Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease.
McNaught KS, Olanow CW. McNaught KS, et al. Ann Neurol. 2003;53 Suppl 3:S73-84; discussion S84-6. doi: 10.1002/ana.10512. Ann Neurol. 2003. PMID: 12666100 Review. - The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
McNaught KS, Jnobaptiste R, Jackson T, Jengelley TA. McNaught KS, et al. Synapse. 2010 Mar;64(3):241-50. doi: 10.1002/syn.20719. Synapse. 2010. PMID: 19924695 - Are ubiquitination pathways central to Parkinson's disease?
Giasson BI, Lee VM. Giasson BI, et al. Cell. 2003 Jul 11;114(1):1-8. doi: 10.1016/s0092-8674(03)00509-9. Cell. 2003. PMID: 12859888 Review.
Cited by
- Nicotinamide riboside first alleviates symptoms but later downregulates dopamine metabolism in proteasome inhibition mouse model of Parkinson's disease.
Turconi G, Alam F, SenGupta T, Pirnes-Karhu S, Olfat S, Schmidt MS, Mätlik K, Montaño-Rodriguez A, Heiskanen V, Garton D, Piepponen PT, Brenner C, Holmberg CI, Nilsen H, Pirinen E, Andressoo JO. Turconi G, et al. Heliyon. 2024 Jul 9;10(14):e34355. doi: 10.1016/j.heliyon.2024.e34355. eCollection 2024 Jul 30. Heliyon. 2024. PMID: 39108921 Free PMC article. - Interaction between α-synuclein and other proteins in neurodegenerative disorders.
Jellinger KA. Jellinger KA. ScientificWorldJournal. 2011;11:1893-907. doi: 10.1100/2011/371893. Epub 2011 Oct 24. ScientificWorldJournal. 2011. PMID: 22125446 Free PMC article. Review. - L-DOPA treatment from the viewpoint of neuroprotection. Possible mechanism of specific and progressive dopaminergic neuronal death in Parkinson's disease.
Ogawa N, Asanuma M, Miyazaki I, Diaz-Corrales FJ, Miyoshi K. Ogawa N, et al. J Neurol. 2005 Oct;252 Suppl 4:IV23-IV31. doi: 10.1007/s00415-005-4006-7. J Neurol. 2005. PMID: 16222434 Review. - Nigral degeneration with inclusion body formation and behavioral changes in rats after proteasomal inhibition.
Niu C, Mei J, Pan Q, Fu X. Niu C, et al. Stereotact Funct Neurosurg. 2009;87(2):69-81. doi: 10.1159/000202972. Epub 2009 Feb 18. Stereotact Funct Neurosurg. 2009. PMID: 19223692 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous